Arcturus Therapeutics Holdings Inc. Stock News

Charles Schwab Investment Management Inc. lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.4% during the second quarter, Holdings Channel reports. The fund owned 144,621 shares of the biotechnology companys stock after acquiring an additional 6,095 shares during the period. Charles Schwab Investment Management Inc.s holdings in Arcturus Therapeutics were worth []

Zacks Investment Research downgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a hold rating to a sell rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system []

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company foc

The company disappointed last year, but things may be turning around.

Three healthcare giants are vying for the prize.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

The company has a specific opportunity to be a vaccine supplier within Asia and to the world.

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) increased by over 35% pre-market. This is why it happened.